Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 3

04:32 EST 24th November 2017 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 51–75 of 7,600+

Probably Relevant

Neon Therapeutics Enters License Agreement With The Netherlands Cancer Institute (NCI) For Neoantigen-Based T Cell Therapeutics

  Life Sciences Jobs   ...


ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

NEW YORK, NY / ACCESSWIRE / November 17, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acorda Therapeutics, Inc. ("Acorda" or the "C...

Proteostasis Therapeutics files IND for PTI-808, cystic fibrosis potentiator

Proteostasis Therapeutics, a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), announced that the company has filed an Investigational New Drug (IND) application with the FDA for PTI-808, its cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. Proteostasis plans to initiate...


Anglo-Japanese collaboration on novel therapeutics in inflammatory disease

UK-based Heptares Therapeutics, a wholly-owned subsidiary of Japan’s Sosei Group, and PeptiDream have…

US FDA Sends Amgen/UCB Evenity Back With BRIDGE Request

The US FDA has surprised no-one with a Complete Response Letter for Amgen and UCB's novel osteoporosis treatment Evenity but...   

Appointments: CRISPR, KSQ Therapeutics, Immunocore, Cellectis, Translate Bio and biOasis

This week's roundup includes CEO appointments by CRISPR Therapeutics and KSQ Therapeutics, in addition to various other board and high-level...    

iTeos Therapeutics: Combating cancer using immunotherapy against novel target combinations

iTeos Therapeutics is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). Focused on expanding the benefits of immunotherapy for cancer patients, the company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-inflamed tumors. Adrian Dawkes speaks to Christophe Queva, CEO of iTeos Therapeutics.

New British Spin-Out Wants to Replace Hormonal Menopause Treatment

KaNDy Therapeutics has been launched as a spin-out of NeRRe Therapeutics to develop a new treatment for menopause that can address multiple symptoms at once. NeRRe Therapeutics, a company built around targeting neurotransmitting peptides, has spun out a single-asset, virtual company named KaNDy Therapeutics that will ... This awesome article New British Spin-Out Wants to Replace Hormonal Men...

Soleno Therapeutics Receives Positive Opinion From European Orphan Committee For DCCR In Prader-Willi Syndrome

REDWOOD CITY, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the European Medicines Agencys (EMA) Committee for Orphan...

Ewing Sarcoma Therapeutics Pipeline Analysis 2017 - Key Players are Pfizer Inc., Merrimack Pharmaceuticals & Celldex Therapeutics

DUBLIN, August 3, 2017 /PRNewswire/ -- The "Ewing Sarcoma Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration and Other Developments" report has be...

Contrasting Sarepta Therapeutics

Sarepta Therapeutics and Arrowhead Pharmaceuticals are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations. Arrowhead Pharmaceuticals has higher revenue, but lower earnings than Sarepta Therapeutics.

Bone Therapeutics et Transgene : 2 cotées qui montrent des signes positifs

La quotidienne de Biotech Finances avec Transgene et Bone Therapeutics Bone Therapeutics (BOTHE), thérapie cellulaire osseuse,  annonce l’obtention de résultats intermédiaires robustes, en termes de sécurité et d’efficacité, pour l’étude de phase IIA évaluant le produit allogénique ALLOB dans la fusion vertébrale lombaire. Les données, issues des 15 premiers patients de l’étud...

Sarepta Therapeutics opens research and manufacturing center in Massachusetts

Sarepta Therapeutics, a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, announced the grand opening of its Research and Manufacturing Center in Andover, Massachusetts. The 60,000 square foot state-of-the-art facility significantly enhances Sarepta’s research and manufact...

Rodeo Therapeutics raises $5.9mm in Series A round

Rodeo Therapeutics Corp. (small-molecule therapeutics for tissue regeneration and repair) raised $5.9mm in its Series A finan...

Soleno Therapeutics Announces Issuance Of New U.S. Patent For DCCR Covering Treatment Of Hyperphagia In Prader-Willi Syndrome

REDWOOD CITY, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the issuance of a new patent (9,782,416) from the U.S. Patent and Trademark Office related...

#jobs #lifescience Senior Product Manager – Therapeutics

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Senior Product Manager – Therapeutics .MA-Weston, The Senior Product Manager – Therapeutics, along with a small team of experienced marketers, is responsible for developing and implementing the overall … Continue reading → Cet article #jobs #lifescience...

Windtree Therapeutics (WINT) versus Oncolytics Biotech (NASDAQ:ONCY) Critical Analysis

Windtree Therapeutics and Oncolytics Biotech are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability. 36.8% of Windtree Therapeutics shares are owned by institutional investors.

Arcturus, Ultragenyx ally in rare disease pact worth up to $1.6bn

RNA-focused start-up Arcturus Therapeutics Inc. (ATI) and fellow rare disease therapeutics developer Ultragenyx Pharmaceutica...

Factor Therapeutics (FTT) - Termination of coverage

Edison Investment Research - Pharmaceutical & healthcare - Factor Therapeutics: Edison Investment Research is terminating coverage on Factor Therapeutics (FTT). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. ISIN: AU000000FTT2

Spark Sets Sights On Bringing First Gene Therapy To Market In 2018

A BLA for a potential gene therapy to correct vision loss due to certain inherited retinal disease has been accepted...   

TR-PHARM Sees Early Success In Mediterranean Fever Antibody

TR-PHARM, a Turkish affiliate of the leading Russian pharma company R-PHARM, has disclosed promising early results for clinical trials with...   

Amylon Therapeutics wins Startup Slam Competition at BIO-Europe® Berlin

Amylon Therapeutics was today announced as the winner of the Startup Slam competition at this year’s BIO-Europe® 2017 annual conference in Berlin. Thomas de Vlaam, CEO and founder of Amylon Therapeutics, will receive a complimentary registration to BIO-Europe® Spring 2018 from EBD Group and the oppo...

Bristol-Myers Squibb to Acquire IFM Therapeutics in $300M Upfront Deal

NewsBristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity. IFM Therapeutics to receive $300 million upfront with potential of up to $1.01 billion in milestones for each of the first products from two programs.

Rebound Therapeutics gets $16.5M boost

Irvine, Calif.-based Rebound Therapeutics raised $16.5 million in a round of Series B financing.  -More- 

CorFlow Therapeutics gets $2.62M boost

A round of seed financing brought in approximately $2.63 million for CorFlow Therapeutics, a Switzerland-based company that i -More- 


Quick Search
Advertisement
 

News Quicklinks